GW Pharmaceuticals Plc American Depositary Shares
GWPH
GWPH was delisted on the 4th of May, 2021.
0 hedge funds and large institutions have $0 invested in GW Pharmaceuticals Plc American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $24K → $0 (-$24K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NEWAS
N.E.W. Advisory Services
De Pere,
Wisconsin
|
-$24K |
GWPH Hedge Fund Activity: Q2 2022 in Review
0 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q2 2022, worth a combined $0 — down 100% from $24K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of GWPH and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was N.E.W. Advisory Services, exiting entirely with an estimated $24K sold.
- 0 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q2 2022, down from 1 in Q1 2022.
- Funds reported $0 of GW Pharmaceuticals Plc American Depositary Shares stock for Q2 2022, down 100% quarter-over-quarter.
- 0 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q2 2022 and 1 closed out, a net change of -1 holder.
- The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q2 2022 was N.E.W. Advisory Services, an estimated $24K sold.
Based on aggregated 13F filings for Q2 2022.